Abstract Body

Weight gain has been reported in virologically suppressed HIV-positive patients who switch to integrase inhibitor (INI)-based antiretroviral therapy (ART). We studied pharmacogenetics of weight gain following switch from efavirenz (EFV)- to INI-based ART.

Patients at an HIV clinic in the southeastern USA were on EFV-based ART for at least 2 years and with no viral load >1000 copies/mL within 6 months prior to switch. Weight gain from date of switch to weeks 24 and/or 48 (± 4 weeks) was assessed. We genotyped [i]CYP2B6[/i] and [i]UGT1A1[/i] polymorphisms that predict increased plasma EFV and INI exposure, respectively. Associations were tested with linear regression models.

The 101 evaluable participants (n=83 for week 24, n=66 for week 48) included 65 (64%) white, 27 (27%) black, 84 (83%) male, and 17 (17%) female participants. INIs were 58 (57%) dolutegravir, 34 (34%) elvitegravir, and 9 (9%) raltegravir. Median baseline weight was 81.7 kg (interquartile range: 69.7, 94.7). There were 30 (30%), 54 (55%), and 15 (15%) CYP2B6 normal, intermediate, and slow metabolizers, respectively, and 38 (40%), 41 (43%), and 16 (17%) UGT1A1 normal, intermediate, and slow metabolizers, respectively. CYP2B6 slow metabolizer genotype was associated with weight gain at week 48 (β= 7.2, p=0.009). In CYP2B6 normal, intermediate, and slow metabolizers, at week 48, average weight gain was 0.2 kg, 2.8 kg and 2.0 kg, respectively. After controlling for sex, age, and weight at switch, associations persisted at week 48 (β=6.97, p=0.012). CYP2B6 genotype was associated with weight gain in whites at week 48 (β=11.25, p=0.003), but not in blacks (β= -0.58, p=0.090) (Figure). The above significant associations also tended to be present at week 24 (p=0.05 to p=0.09). UGT1A1 genotype was not associated with weight change at week 24 (β= -0.33, p=0.83) or week 48 (β=0.70, p=0.77).

Among virologically suppressed patients who switch from EFV-based ART to INI-based ART, CYP2B6 genotype that is known to predict higher EFV plasma exposure pre-switch may be associated with greater weight gain after switch. These findings warrant replication in other cohorts. We hypothesize that patients with greater plasma EFV concentrations before switch may have sub-clinical intolerance. These patients may therefore gain more weight after switch from EFV-based ART to INI-based ART.